VivoSeq
Psychiatry

Depression

14

Pipeline Programs↗

87

Active Trials↗

35

Companies Involved↗

Depression is an emerging landscape with 14 programs across 35 companies. The most active players are Amgen, Novartis, COMPASS Pathways. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

59/100

Mech. Concentration

13/100

Completion Rate

83/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 2COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

397

clinical trials

Completed230 · 58%
Recruiting57 · 14%
Unknown status34 · 9%
Terminated34 · 9%
Not yet recruiting15 · 4%
Active, not recruiting14 · 4%
Other13 · 3%

Clinical Trials

Trial Activity

397 trials

Psychoeducational Group for Depression
Recruiting·RRicardo Alberto Moreno, M.D., Ph.D.·N/A·NCT06467474·338 enrolled
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
Recruiting·AAmsterdam UMC, location VUmc·Phase 3·NCT05415397·140 enrolled
Depression and Driving
Recruiting·—·N/A·NCT05446805·150 enrolled
OSU6162 as add-on in SSRI/SNRI-resistant Depression
Recruiting·GGöteborg University·Phase 2·NCT05641623·180 enrolled
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II
Recruiting·WWashington University School of Medicine·Phase 2·NCT06867549·70 enrolled
Improvement of Depression With Use of ATP
Recruiting·NNanfang Hospital, Southern Medical University·N/A·NCT06266715·120 enrolled
Pharmacologic Treatment Augmentation in Chronic Depression
Recruiting·UUniversity Hospital Tuebingen·Phase 2·NCT06410599·60 enrolled
Trial of Mirtazapine for Depression in IBD
Recruiting·KKing's College London·Phase 2·NCT06309472·76 enrolled
Improving Outcomes in Depression in Primary Care in a Low Resource Setting
Recruiting·HHarvard Medical School (HMS and HSDM)·Phase 3·NCT05944926·1,500 enrolled
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Recruiting·UUniversity of Texas at Austin·Phase 4·NCT05892744·50 enrolled
A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems
Recruiting·ZZhenghui YI·Phase 4·NCT05599126·300 enrolled
Leucine in Midlife Depression
Recruiting·EEmory University·Phase 2·NCT06580145·75 enrolled
JAK Signaling in Depression
Recruiting·EEmory University·Phase 2·NCT07003997·100 enrolled
Brexpiprazole Treatment for Bipolar I Depression
Recruiting·—·Phase 3·NCT04569448·58 enrolled
Identifying and Treating Depression in the Orthopaedic Trauma Population
Recruiting·WWake Forest University Health Sciences·Phase 4·NCT05976347·100 enrolled
Page 1 of 27

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)